Short-Term Shareholder Value Boost From Cardio3’s CorQuest Buy
Cardio3 BioSciences believes that income in the “several hundred million euros” range could eventually result from its purchase of US company CorQuest Medical’s minimally invasive cardiac surgery technologies, but the acquisition will first and foremost allow the Belgian company to make major strides in creating short-term value for shareholders.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.